Both ACP and The BMJ completed evidence reviews and issued recommendations on use of certain drugs for COVID-19. Another article warned about Strongyloides hyperinfection, a potentially dangerous side effect of dexamethasone for some patients.
Somewhere deep inside, there was hope that the need to apply this information might never arrive.
A British study highlighted the disproportionate effect of COVID-19 on black pregnant women, and articles by physicians urged action against racism and racial disparities.
The 2019 novel coronavirus, which causes coronavirus disease (COVID-19), should be coded with the ICD-10 code B97.29, other coronavirus as the cause of diseases classified elsewhere.
Remdesivir showed limited benefits, antibiotics have been overused, and intubation timing doesn't matter, but postdischarge outcomes were reassuring and infectious diseases experts offered guidance on the use of antibody tests in recent COVID-19 news
Hospitalizations for stroke and myocardial infarction, ED visits, cancer diagnoses, and trials for conditions other than COVID-19 all dropped during the pandemic, recent studies showed.
New guidance from ACP and recent trials do not support the use of hydroxychloroquine for COVID-19, and a pharmacokinetic analysis showed potential problems with lopinavir/ritonavir therapy.
A new CHEST guideline supports standard-dose anticoagulant thromboprophylaxis, while authors of two recent studies of hypercoagulability called for higher doses.
he has held since 1984, and as a member of the White House Coronavirus Task Force. ... In] coronavirus infections that are non-COVID, the ones that are the common cold, protection usually lasts about six months to a year.
Trials have found some potential benefit from remdesivir, early treatment with methylprednisolone, and measurement of C-reactive protein. Early vaccine trial results and guidance on antibody testing were also recently released.